Your session is about to expire
← Back to Search
Nivolumab Combinations for Prostate Cancer (CheckMate 9KD Trial)
CheckMate 9KD Trial Summary
This trial is testing nivolumab in combination with other drugs to see if it is safe and effective in treating prostate cancer that has spread and is resistant to hormone therapy.
CheckMate 9KD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCheckMate 9KD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 1844 Patients • NCT03068455CheckMate 9KD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had any cancer except for minor skin, bladder, or early-stage breast cancer in the last 3 years.Other specific requirements for participating in the study may exist.My scans show my cancer is stage IV.I am currently on hormone therapy for cancer or have had surgery to remove my testicles.I have active cancer spread to my brain.I can provide samples of my blood and either a new or stored sample of my tumor.My prostate cancer is confirmed to be adenocarcinoma.I have recovered from major surgery or a serious injury for at least 14 days.
- Group 1: nivolumab + rucaparib
- Group 2: nivolumab + docetaxel + prednisone
- Group 3: nivolumab + enzalutamide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many facilities are facilitating this trial?
"This clinical trial can be found at Maryland Oncology Hematology, P.A. in Rockville, Maryland; Local Institution - 0068 in New york City and Local Institution - 0038 in Albany, Mississippi as well another 42 research sites throughout the country."
Are there any vacancies for participants in this research program?
"Unfortunately, clinicaltrials.gov states that this trial is not currently recruiting patients to participate. The first posting of the study occurred on December 19th 2017 and it was last updated on October 4th 2022. Nevertheless, there are a multitude of other medical studies seeking volunteers presently with 2745 trials open for enrollment at present."
What is the recruitment rate for this clinical research program?
"Unfortunately, this research project has already stopped recruitment. Initial postings for the trial were made on December 19th 2017 and it was last updated on October 4th 2022. For those seeking alternate trials, there are currently 1,321 prostate cancer studies and 1,424 clinical tests involving nivolumab that are actively enrolling participants."
What health conditions has nivolumab been found to effectively address?
"Nivolumab is a popular treatment for thyroiditis, as well as unresectable melanoma and squamous cell carcinomas. This medication can also be used to manage ulcerative colitis symptoms."
Has nivolumab been used in any other scientific research?
"Presently, there are 1424 ongoing clinical investigations exploring nivolumab with 309 of these in the third phase. Most of these trials are based out of Columbus, Ohio however over seventy-nine thousand locations worldwide have studies for this drug running."
Could you elucidate the risks of using nivolumab as a treatment option?
"A score of 2 was assigned to nivolumab due to the lack of clinical efficacy data, although there is evidence which suggests it has a positive safety profile."
Share this study with friends
Copy Link
Messenger